Preclinical studies also show promise for CCL5 antagonists in pancreatic cancer and bone-metastatic breast cancer, and a current phase 1 clinical trial (NCT04721301) is investigating the combination of Maraviroc with other immunotherapies in metastatic colorectal and pancreatic cancer patients (241, 242). The gene discussed is CCL5; the disease is familial pancreatic carcinoma.